Ascendis Pharma A/S expected to post a loss of €2.00 a share - Earnings Preview

Ascendis Pharma A/S

10/05/2022 03:04

* Ascendis Pharma A/S  ASND.OQ   ASND.O  is expected to show
a
rise in quarterly revenue when it reports  results on May 11. 
    * The Hellerup Denmark-based   company is expected to report
 a
526.4% increase in revenue to €4.673 million from €746 thousand
a year ago, according to the mean estimate from 10 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Ascendis Pharma A/S
is
for a loss of €2.00 per share. For the same quarter last year,
the company reported a loss of €1.17 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $191​, above​ its last closing price of $78.90. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in euros). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -2.39       -2.34      -1.87     Beat    20.2
 Sep. 30 2021  -2.30       -2.29      -1.47     Beat    35.9
 Jun. 30 2021  -2.22       -2.23      -2.50     Missed  -12.3​
 Mar. 31 2021  -1.70       -1.71      -1.17     Beat    31.4
 ​​Dec.        -1.59       -1.55      -2.64     Missed  -70.3
 31 2020                                                
 Sep. 30 2020  -1.58       -1.57      -2.31     Missed  -46.7​
 Jun. 30 2020  -1.46       -1.45      -1.97     Missed  -35.6
 Mar. 31 2020  -1.36       -1.35      -1.32     Beat    2.1
 This summary was machine generated May 10 at 02:04 GMT.  All
figures in euros  unless otherwise stated